Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis

Journal of Immunology

Volumn 181, Issue 6, 2008, Pages 4208-4218

  Ishida, Yuko ^a   Hayashi, Takahito ^a,c   Goto, Takatsugu ^a,d   Kimura, Akihiko ^a   Akimoto, Shigeru ^a   Mukaida, Naofumi ^b   Kondo, Toshikazu ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, MOUSE; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CELL FUNCTION; CELL INFILTRATION; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HOST RESISTANCE; IN VITRO STUDY; LEUKOCYTE; LIGATION; MACROPHAGE; MALE; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; PERITONEUM; PERITONITIS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PUNCTURE; SEPSIS; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CECUM; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; ENTEROBACTER INFECTION; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MICROBIOLOGY; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PERITONEUM MACROPHAGE; PHYSIOLOGY; SEPTIC SHOCK; SERUM BACTERICIDAL ACTIVITY;

ANIMALS; BLOOD BACTERICIDAL ACTIVITY; CECUM; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; LIGATION; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; PERITONITIS; PUNCTURES; RECEPTORS, CHEMOKINE; SHOCK, SEPTIC; SIGNAL TRANSDUCTION;

EID: 56149116902     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.6.4208     Document Type: Article

References (63)

1. Annane, D., E. Bellissant, and J. M. Cavaillon. 2005. Septic shock. Lancet 365: 63-78.
2. Russell, J. A. 2006. Management of sepsis. N. Engl. J. Med. 355: 1699-1713.
3. Brown, K. A., S. D. Brain, J. D. Pearson, J. D. Edgeworth, S. M. Lewis, and D. F. Treacher. 2006. Neutrophils in development of multiple organ failure in sepsis. Lancet 368: 157-169. (Pubitemid 43994173)
4. Holzheimer, R. G., K. H. Muhrer, N. L'Allemand, T. Schmidt, and K. Henneking. 1991. Intraabdominal infections: classification, mortality, scoring, and pathophysiology. Infection 19: 447-452.
5. Fisher, C. J., Jr., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: the Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334: 1697-1702.
6. Abraham, E., R. Wunderink, H. Silverman, T. M. Perl, S. Nasraway, H. Levy, R. Bone, R. P. Wenzel, R. Balk, R. Allred, et al. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. J. Am. Med. Assoc. 273: 934-941.
7. Abraham, E., M. P. Glauser, T. Butler, J. Garbino, D. Gelmont, P. F. Laterr, K. Kudsk, H. A. Bruining, C. Otto, E. Tobin, et al. 1997. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial: Ro 45-2081 Study Group. J. Am. Med. Assoc. 277: 1531-1538. (Pubitemid 27213302)
8. Fisher, C. J., Jr., G. J. Slotman, S. M. Opal, J. P. Pribble, R. C. Bone, G. Emmanuel, D. Ng, D. C. Bloedow, and M. A. Catalano. 1994. IL-1RA Sepsis Syndrome Study Group: initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22: 12-21.
9. Mukaida, N. 2003. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. 284: L566-L577.
10. Mukaida, N. 2000. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int. J. Hematol. 72: 391-398.
11. Fong, A. M., L. A. Robinson, D. A. Steeber, T. F. Tedder, O. Yoshie, T. Imai, and D. D. Patel. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188: 1413-1419.
12. Bazan, J. F., K. B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D. R. Greaves, A. Zlotnik, and T. J. Schall. 1997. A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644.
13. Imai, T., K. Hieshima, C. Haskell, M. Baba, M. Nagira, M. Nishimura, M. Kakizaki, S. Takagi, H. Nomiyama, T. J. Schall, and O. Yoshie. 1997. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530. (Pubitemid 27508241)
14. Cook, D. N., S. C. Chen, L. M. Sullivan, D. J. Manfra, M. T. Wiekowski, D. M. Prosser, G. Vassileva, and S. A. Lira. 2001. Generation and analysis of mice lacking the chemokine fractalkine. Mol. Cell. Biol. 21: 3159-3165.
15. 3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20: 4106-4114.
16. Haskell, C. A., W. W. Hancock, D. J. Salant, W. Gao, V. Csizmadia, W. Peters, K. Faia, O. Fituri, J. B. Rottman, and I. F. Charo. 2001. Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. J. Clin. Invest. 108: 679-688.
17. Furuichi, K., J. L. Gao, and P. M. Murphy. 2006. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am. J. Pathol. 169: 372-387. (Pubitemid 44156300)
18. Combadiere, C., S. Potteaux, J. L. Gao, B. Esposito, S. Casanova, E. J. Lee, P. Debr, A. Tedgui, P. M. Murphy, and Z. Mallat. 2003. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009-1016. (Pubitemid 36258725)
19. -/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111: 333-340.
20. Teupser, D., S. Pavlides, M. Tan, J. C. Gutierrez-Ramos, R. Kolbeck, and J. L. Breslow. 2004. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc. Natl. Acad. Sci. USA 101: 17795-17800. (Pubitemid 40051966)
21. Barlic, J., Y. Zhang, J. F. Foley, and P. M. Murphy. 2006. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway. Circulation 114: 807-819. (Pubitemid 44268231)
22. Tacke, F., D. Alvarez, T. J. Kaplan, C. Jakubzick, R. Spanbroek, J. Llodra, A. Garin, J. Liu, M. Mack, N. van Rooijen, et al. 2007. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117: 185-194. (Pubitemid 46048465)
23. + individuals with a structural variant of the chemokine receptor CX3CR1. Science 287: 2274-2277.
24. McDermott, D. H., A. M. Fong, Q. Yang, J. M. Sechler, L. A. Cupples, M. N. Merrell, P. W. Wilson, R. B. D'Agostino, C. J. O'Donnell, D. D. Patel, and P. M. Murphy. 2003. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 111: 1241-1250.
25. Ness, T. L., C. M. Hogaboam, R. M. Strieter, and S. L. Kunkel. 2003. Immunomodulatory role of CXCR2 during experimental septic peritonitis. J. Immunol. 171: 3775-3784. (Pubitemid 37254583)
26. Matsukawa, A., S. Kudoh, G. Sano, T. Maeda, T. Ito, N. W. Lukacs, C. M. Hogaboam, S. L. Kunkel, and S. A. Lira. 2006. Absence of CC chemokine receptor 8 enhances innate immunity during septic peritonitis. FASEB J. 20: 302-304. (Pubitemid 46671151)
27. Ness, T. L., K. J. Carpenter, J. L. Ewing, C. J. Gerard, C. M. Hogaboam, and S. L. Kunkel. 2004. CCR1 and CC chemokine ligand 5 interactions exacerbate innate immune responses during sepsis. J. Immunol. 173: 6938-6948.
28. Gomes, R. N., R. T. Figueiredo, F. A. Bozza, P. Pacheco, R. T. Amancio, A. P. Laranjeira, H. C. Castro-Faria-Neto, P. T. Bozza, and M. T. Bozza. 2006. Increased susceptibility to septic and endotoxic shock in monocyte chemoattractant protein 1/CC chemokine ligand 2-deficient mice correlates with reduced interleukin 10 and enhanced macrophage migration inhibitory factor production. Shock 26: 457-463.
29. Matsukawa, A., C. M. Hogaboam, N. W. Lukacs, P. M. Lincoln, H. L. Evanoff, and S. L. Kunkel. 2000. Pivotal role of the CC chemokine, macrophage-derived chemokine, in the innate immune response. J. Immunol. 164: 5362-5368. (Pubitemid 30305216)
30. Matsukawa, A., C. M. Hogaboam, N. W. Lukacs, P. M. Lincoln, R. M. Strieter, and S. L. Kunkel. 1999. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J. Immunol. 163: 6148-6154.
31. Nakano, Y., T. Kasahara, N. Mukaida, Y. C. Ko, M. Nakano, and K. Matsushima. 1994. Protection against lethal bacterial infection in mice by monocyte-chemotactic and -activating factor. Infect. Immun. 62: 377-383. (Pubitemid 24033752)
32. Kimura, A., Y. Ishida, T. Hayashi, T. Wada, H. Yokoyama, T. Sugaya, N. Mukaida, and T. Kondo. 2006. Interferon-γ plays protective roles in sodium arsenite-induced renal injury by up-regulating intrarenal multidrug resistance-associated protein 1 expression. Am. J. Pathol. 169: 1118-1128. (Pubitemid 351194350)
33. Ishida, Y., T. Kondo, A. Kimura, K. Matsushima, and N. Mukaida. 2006. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-κB activation and a reciprocal suppression of TGF-β signal pathway. J. Immunol. 176: 5598-5606.
34. Watanabe, H., M. Kubo, K. Numata, K. Takagi, H. Mizuta, S. Okada, T. Ito, and A. Matsukawa. 2006. Overexpression of suppressor of cytokine signaling-5 in T cells augments innate immunity during septic peritonitis. J. Immunol. 177: 8650-8657. (Pubitemid 44893829)
35. Matsukawa, A., K. Takeda, S. Kudo, T. Maeda, M. Kagayama, and S. Akira. 2003. Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. J. Immunol. 171: 6198-6205. (Pubitemid 37467243)
36. Moreno, S. E., J. C. Alves-Filho, T. M. Alfaya, J. S. da Silva, S. H. Ferreira, and F. Y. Liew. 2006. IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J. Immunol. 177: 3218-3224.
37. Nathan, C. F., and J. B. Hibbs, Jr. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3: 65-70.
38. Garcia, G. E., Y. Xia, S. Chen, Y. Wang, R. D. Ye, J. K. Harrison, K. B. Bacon, H. G. Zerwes, and L. Feng. 2000. NF-κB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1β, TNF-α, and LPS. J. Leukocyte Biol. 67: 577-584.
39. Sanchez, M. S., C. W. Ford, and R. J. Yancey, Jr. 1994. Effect of tumor necrosis factor-α, interleukin-1 β, and antibiotics on the killing of intracellular Staphylococcus aureus. J. Dairy Sci. 77: 1251-1258.
40. Steinhauser, M. L., C. M. Hogaboam, N. W. Lukacs, R. M. Strieter, and S. L. Kunkel. 1999. Multiple roles for IL-12 in a model of acute septic peritonitis. J. Immunol. 162: 5437-5443.
41. Malaviya, R., T. Ikeda, E. Ross, and S. N. Abraham. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF. Nature 381: 77-80. (Pubitemid 26130006)
42. Moreira, A. L., L. Tsenova, P. J. Murray, S. Freeman, A. Bergtold, L. Chiriboga, and G. Kaplan. 2000. Aerosol infection of mice with recombinant BCG secreting murine IFN-γ partially reconstitutes local protective immunity. Microb. Pathog. 29: 175-185.
43. Meucci, O., A. Fatatis, A. A. Simen, T. J. Bushell, P. W. Gray, and R. J. Miller. 1998. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc. Natl. Acad. Sci. USA 95: 14500-14505. (Pubitemid 28549396)
44. Maciejewski-Lenoir, D., S. Chen, L. Feng, R. Maki, and K. B. Bacon. 1999. Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J. Immunol. 163: 1628-1635. (Pubitemid 29352788)
45. Brand, S., T. Sakaguchi, X. Gu, S. P. Colgan, and H. C. Reinecker. 2002. Fractalkine-mediated signals regulate cell-survival and immune-modulatory responses in intestinal epithelial cells. Gastroenterology 122: 166-177. (Pubitemid 34049205)
46. Chandrasekar, B., S. Mummidi, R. P. Perla, S. Bysani, N. O. Dulin, F. Liu, and P. C. Melby. 2003. Fractalkine (CX3CL1) stimulated by nuclear factor κB (NF-κB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem. J. 373: 547-558. (Pubitemid 36897857)
47. Volin, M. V., N. Huynh, K. Klosowska, K. K. Chong, and J. M. Woods. 2007. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum. 56: 2512-2522.
48. Takahashi, H., T. Tashiro, M. Miyazaki, M. Kobayashi, R. B. Pollard, and F. Suzuki. 2002. An essential role of macrophage inflammatory protein 1α/CCL3 on the expression of host's innate immunities against infectious complications. J. Leukocyte Biol. 72: 1190-1197. (Pubitemid 36008890)
49. Bhattacharyya, S., S. Ghosh, B. Dasgupta, D. Mazumder, S. Roy, and S. Majumdar. 2002. Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. J. Infect. Dis. 185: 1704-1708. (Pubitemid 34615462)
50. Garton, K. J., P. J. Gough, C. P. Blobel, G. Murphy, D. R. Greaves, P. J. Dempsey, and E. W. Raines. 2001. Tumor necrosis factor-α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276: 37993-38001. (Pubitemid 37384050)
51. Geissmann, F., S. Jung, and D. R. Littman. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82. (Pubitemid 36859902)
52. + monocytes. J. Exp. Med. 197: 1701-1707.
53. Feng, L., S. Chen, G. E. Garcia, Y. Xia, M. A. Siani, P. Botti, C. B. Wilson, J. K. Harrison, and K. B. Bacon. 1999. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int. 56: 612-620. (Pubitemid 29353159)
54. Ishida, Y., J. L. Gao, and P. M. Murphy. 2008. Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J. Immunol. 180: 569-579.
55. Kurihara, T., G. Warr, J. Loy, and R. Bravo. 1997. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186: 1757-1762. (Pubitemid 27506288)
56. Boring, L., J. Gosling, S. W. Chensue, S. L. Kunkel, R. V. Farese, Jr., H. E. Broxmeyer, and I. F. Charo. 1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100: 2552-2561. (Pubitemid 27514895)
57. Kuziel, W. A., S. J. Morgan, T. C. Dawson, S. Griffin, O. Smithies, K. Ley, and N. Maeda. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA 94: 12053-12058.
58. + monocytes is essential for control of acute toxoplasmosis. J. Exp. Med. 201: 1761-1769.
59. Green, S. R., K. H. Han, Y. Chen, F. Almazan, I. F. Charo, Y. I. Miller, and O. Quehenberger. 2006. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J. Immunol. 176: 7412-7420.
60. Serbina, N. V., T. P. Salazar-Mather, C. A. Biron, W. A. Kuziel, and E. G. Pamer. 2003. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19: 59-70.
61. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145.
62. O'Neill, L. A. 2006. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 5: 549-563.
63. Barton, G. M., and R. Medzhitov. 2003. Toll-like receptor signaling pathways. Science 300: 1524-1525.